Aeterna Zentaris Casts a Lifeline

Aeterna Zentaris (Nasdaq: AEZS  ) dropped over 10% after executing a six-for-one reverse stock split to boost its share price and regain compliance with Nasdaq rules, in order to stay listed.

The company has had a rough go of it ever since perifosine, its etastatic colorectal cancer drug, failed to meet its endpoint in late-stage clinical trials. AEZS has almost $40MM in cash, but it's burned through $34MM over the past 12 months as it advances drugs through four mid-stage trials, and two late-stage trials, including perifosine in other cancer indications. analyst Dave Williamson is glad that Aeterna Zentaris will remain listed, but he advises investors to hold off until the company is able to show more trial results. For Dave's full take on the story, be sure to check out the video below.


While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Dave Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2046555, ~/Articles/ArticleHandler.aspx, 3/27/2015 6:23:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!